Cidara Therapeutics, Inc. (NASDAQ:CDTX) was the recipient of a large decline in short interest during the month of August. As of August 15th, there was short interest totalling 536,961 shares, a decline of 53.3% from the July 31st total of 1,149,372 shares. Based on an average daily trading volume, of 109,766 shares, the short-interest ratio is presently 4.9 days. Approximately 5.6% of the company’s stock are sold short.

In other Cidara Therapeutics news, insider Taylor Sandison purchased 20,000 shares of the stock in a transaction on Wednesday, June 7th. The shares were purchased at an average cost of $5.90 per share, for a total transaction of $118,000.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Jeffrey Stein purchased 15,000 shares of the stock in a transaction on Monday, June 5th. The stock was acquired at an average price of $5.95 per share, for a total transaction of $89,250.00. The disclosure for this purchase can be found here. 18.90% of the stock is currently owned by insiders.

Hedge funds have recently made changes to their positions in the stock. Trexquant Investment LP purchased a new stake in shares of Cidara Therapeutics during the second quarter valued at approximately $110,000. Teachers Advisors LLC increased its stake in shares of Cidara Therapeutics by 17.5% in the fourth quarter. Teachers Advisors LLC now owns 16,524 shares of the biotechnology company’s stock valued at $172,000 after buying an additional 2,458 shares in the last quarter. Citadel Advisors LLC purchased a new stake in shares of Cidara Therapeutics during the second quarter valued at approximately $129,000. Raymond James Financial Services Advisors Inc. purchased a new stake in shares of Cidara Therapeutics during the second quarter valued at approximately $131,000. Finally, JPMorgan Chase & Co. increased its stake in shares of Cidara Therapeutics by 455.6% in the first quarter. JPMorgan Chase & Co. now owns 25,639 shares of the biotechnology company’s stock valued at $200,000 after buying an additional 21,024 shares in the last quarter. Institutional investors own 66.10% of the company’s stock.

Cidara Therapeutics (NASDAQ CDTX) opened at 7.20 on Friday. The stock has a 50 day moving average of $7.04 and a 200-day moving average of $7.16. The company’s market cap is $121.41 million. Cidara Therapeutics has a 12 month low of $5.60 and a 12 month high of $12.95.

Cidara Therapeutics (NASDAQ:CDTX) last announced its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.99) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.91) by $0.08. Equities research analysts expect that Cidara Therapeutics will post ($3.62) EPS for the current year.

A number of brokerages have recently commented on CDTX. Cantor Fitzgerald set a $15.00 price objective on shares of Cidara Therapeutics and gave the company a “buy” rating in a research report on Saturday, June 24th. WBB Securities raised shares of Cidara Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, August 11th. ValuEngine downgraded shares of Cidara Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday. Zacks Investment Research raised shares of Cidara Therapeutics from a “hold” rating to a “buy” rating and set a $7.75 price objective for the company in a research report on Monday, June 19th. Finally, Wedbush reissued an “outperform” rating and issued a $13.00 price objective on shares of Cidara Therapeutics in a research report on Tuesday, May 16th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. Cidara Therapeutics currently has an average rating of “Buy” and an average price target of $13.14.

WARNING: “Short Interest in Cidara Therapeutics, Inc. (CDTX) Decreases By 53.3%” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The correct version of this report can be read at https://www.thecerbatgem.com/2017/09/02/short-interest-in-cidara-therapeutics-inc-cdtx-decreases-by-53-3.html.

Cidara Therapeutics Company Profile

Cidara Therapeutics, Inc, formerly K2 Therapeutics, Inc, is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections.

Receive News & Stock Ratings for Cidara Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics Inc. and related stocks with our FREE daily email newsletter.